Hidradenitis Suppurativa: Trends in Real-World Treatment Patterns in the United States
An OMNY Health™ Poster
Given the changing treatment landscape, it is important to understand current treatment patterns for hidradenitis suppurativa (HS)
On May 15 – May 18, 2022, this poster was on display at ISPOR 2022.
Conclusions:
- Results provide insights into real-world treatment patterns for HS within a diverse set of US healthcare settings.
- Adalimumab use has increased steadily since the Food and Drug Administration approval for the treatment of HS, while incision/drainage procedures and laser surgeries have both seen steady declines.
- As new treatments are developed and introduced, further analyses would be helpful to understand uptake of therapies and prescription patterns among HS patients.